--- title: "Weekly Recap | Eli Lilly +3.19%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/301468663.md" description: "Eli Lilly (LLY) rose 3.19% this week to close at $1,179.27, outpacing the S&P 500 by roughly 2.04 percentage points. The week started cautiously, with Monday and Tuesday trading between $1,139 and $1,177. Wednesday saw a momentum push to an intraday high of $1,206.63, Thursday gave back most of those gains before dipping to $1,131.21, and Friday recovered to finish near the weekly high. Weekly amplitude was 6.55%, with average daily volume of 2." datetime: "2026-10-10T07:00:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/301468663.md) - [en](https://longbridge.com/en/news/301468663.md) - [zh-HK](https://longbridge.com/zh-HK/news/301468663.md) generator: "portal-rs" --- # Weekly Recap | Eli Lilly +3.19%, most brokers rate it buy ## The Week Eli Lilly (LLY) rose 3.19% this week to close at $1,179.27, outpacing the S&P 500 by roughly 2.04 percentage points. The week started cautiously, with Monday and Tuesday trading between $1,139 and $1,177. Wednesday saw a momentum push to an intraday high of $1,206.63, Thursday gave back most of those gains before dipping to $1,131.21, and Friday recovered to finish near the weekly high. Weekly amplitude was 6.55%, with average daily volume of 2.18m shares, slightly below the 60-day median. ## Key Events Lilly’s news flow this week centred on expanded indications and external partnerships. On Monday, the FDA approved an expanded indication for Jaypirca, and Lilly presented new Phase 3 ADorable-1 data for EBGLYSS in paediatric atopic dermatitis at Fall Clinical 2026. Midweek, Lilly expanded its drug discovery collaboration with Gate Bioscience to more than $870m with an additional target, which helped lift the share price on Tuesday and Wednesday. On Thursday, Lilly released Phase 3b TOGETHER-PsO data showing Taltz plus Zepbound produced broader immune and metabolic biomarker changes than Taltz alone. On the policy side, the WHO’s childhood obesity guidelines — suggesting lifestyle changes before weight-loss medication in children — added uncertainty around the longer-term adoption of GLP-1 treatments. ## Analyst Ratings Analyst coverage stands at 32 institutions, with 19 buy ratings, 6 overweight, 3 hold, 1 underweight, 1 sell and 2 with no clear view. The consensus recommendation is buy, with a consensus target of $1,330.14, about 12.79% above the current price. Target prices range widely from $930 to $1,600, indicating sharp disagreement. Lilly ranks 1st within the pharmaceutical industry among 203 companies. ## The Week Ahead The next catalyst is US CPI on 14 October, with headline CPI at 3.4% prior (3.7% forecast) and core CPI at 2.4% prior (2.5% forecast). Inflation prints will shape rate expectations and influence high-valuation growth names. Lilly’s own Q3 earnings land on 29 October, with consensus EPS around $8.08 and revenue near $22.4bn — Zepbound and Mounjaro sales trends will be the main focus. ## In Short Lilly’s advance this week reflects two opposing forces: positive company-specific news and broad analyst support, with the consensus target sitting above spot; against a rich valuation at roughly 41.6x P/E and 32.8x P/B, plus policy uncertainty around paediatric use of weight-loss drugs. The path forward hinges on how CPI shapes the rate narrative, and whether Q3 results justify the current multiple. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md) - [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md) ## Related News & Research - [Correction to Eli Lilly's Omvoh Hits Goal in Phase 3 Study Article on Oct. 19](https://longbridge.com/en/news/302438751.md) - [Eli Lilly and Company $LLY Shares Sold by Essential Planning LLC.](https://longbridge.com/en/news/302956671.md) - [Eli Lilly and Company $LLY Shares Sold by USAdvisors Wealth Management LLC](https://longbridge.com/en/news/302964762.md) - [Sun rises on a new Leqselvi marketing era with first DTC ad](https://longbridge.com/en/news/303239342.md) - [Eli Lilly Plans Pediatric Omvoh Expansion After Phase 3 Trial Win](https://longbridge.com/en/news/302313582.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**